Phase 2 N=25 Postmenopausal Women Estrogen and Progesterone Infusion
Postmenopause · Aging
Primary: Effect of Aging on Estrogen Negative Feedback on LH — -52.8; -53.2 % change from baseline — p=0.90
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,083 Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
Endometrial Hyperplasia · Osteoporosis
Primary: Percentage of Participants With Hyperplasia at Screening
Phase 4 N=24 Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function
Cardiovascular Diseases
Primary: Brachial Artery Reactivity % Flow Mediated Dilation (BAR %FMD) — 5.49; 3.39 % FMD after 6 weeks of treatment — p=0.04
N/A N=53 Timing Estrogen After MenoPaUSe
Insulin Resistance
Primary: Insulin-mediated Glucose Disposal Rate (Hyperinsulinemic-euglycemic Clamp) — 11.7; 11.5; 12.2; 10.7 mg/kg FFM/min
Phase 3 N=1,271 Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
Hypoactive Sexual Desire Disorder
Primary: Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Not Using Concomitant Estrogen and Progestin, Year 1…
Phase 3 N=20 Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women
Menopause
Primary: Vaginal Cytokines at Baseline — 2.73; 3.19; 0.12; 0.04 pg/ug protein
Phase 3 N=172 Perimenopausal Estrogen Replacement Therapy Study
Perimenopause · Menopause · Depression
Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale
N/A N=30 Early Menopause Hormone Treatment and Cognition
Menopausal Syndrome
Primary: Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans — .14; .13; .05; .13 percent BOLD signal…
Phase 2 N=96 Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women
Human Immunodeficiency Virus
Primary: Safety of Dapivirine (25 mg) Administered in a Silicone Elastomer Vaginal Matrix Ring in HIV-uninfected Postmenopausal Women, When Inserted Once Every 4 Weeks During 12…
Phase 1 N=29 A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women
Postmenopausal Symptoms
Primary: Immunohistochemistry (IHC) Proliferative Effects Measurement — 0.73; 0.43; 0.25 Square root of % positive stained cells — p=<0.001
N/A N=19 Role of T-cells in Post-Menopausal Osteoporosis
Osteoporosis
Primary: Changes in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells — 3.6; 1.8 percentage of CD3 positive cells
Phase 2 N=374 MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
Menopause Hot Flashes
Primary: Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12 — -1.92; -2.75; -2.75; -1.39 VMS per day
Phase 2 N=11 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA) — 2.0 percent change
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
Phase 4 N=109 Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
Bone Loss · Osteoporosis · Breast Cancer
Primary: BMD of Spine by DXA — 2.269; -1.735 percentage change
Phase 3 N=443 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
Breast Cancer · Gynecologic Cancer
Primary: Alleviation of the Most Bothersome Vaginal Symptom (Vaginal Dryness or Dyspareunia) Over 12 Weeks — -2; -2; -1 change in units on a scale — p=0.08
Phase 2 N=36 Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
Breast Cancer · Stage II Breast Cancer · Stage III Breast Cancer
Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants
Phase 3 N=764 Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
Vulvovaginal Atrophy · Menopause · Dyspareunia
Primary: Co-Primary Efficacy Endpoint - Vaginal Superficial Cells — 17.50; 16.72; 23.20; 5.63 percentage of vaginal superficial cells — p=< 0.0001
Phase 2 N=190 Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
Vasomotor Symptoms (VMS)
Primary: Percentage of Subjects With Adverse Events — 56.7 percentage of subjects
Phase 2 N=6 Exemestane in Post-Menopausal Women With NSCLC
Non-Small Cell Lung Cancer
Primary: Disease Response (RECIST) — NA days
Phase 3 N=1,886 Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
Menopause · Osteoporosis
Primary: Percentage of Participants With Endometrial Hyperplasia at Month 12: Main Study — 0.30; 0.54; 0.00; 0.00 Percentage of Participants
N/A N=1,036,294 A Study to Learn More About the Menopausal Hormone Therapies in Korea
Menopause · Bone Demineralization
Primary: Number of Women Who Visited Hospitals for Menopausal Symptoms Distributed Per Year — 786616; 787425; 791890; 818749 Participants
Phase 2 N=29 Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women
Estrogen Deficiency · Cardiovascular Disease (CVD) · Functional Hypothalamic Amenorrhea
Primary: Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry — 0.20; 0.25 change of RHI
Phase 3 N=1,845 A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
Menopause
Primary: Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS) — -40.6; -35.1; -33.6; -38.9 weekly hot flushes — p=<0.001
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
Phase 2 N=61 Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
Breast Cancer Female
Primary: Measure Ki67 Index in Highly Hormone-dependent Breast Cancers vs. Those That Are Not — 7; 6; 40 Participants
Phase 3 N=189 Progesterone for Perimenopausal Night Sweats
Hot Flushes · Night Sweats
Primary: Vasomotor Symptoms (VMS)/ VMS Score - at 12 Weeks — 5.5; 7.1 Units of Vasomotor Symptom Score
Phase 4 N=63 Raloxifene and Rimostil for Perimenopause-Related Depression
Perimenopausal Depression · Depression
Primary: Center for Epidemiologic Studies-Depression Scale (CES-D) — 27.4; 29.1; 28.8; 24.6 Units on a scale
Phase 4 N=79 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women
Overweight
Primary: Body Composition: Dual-energy X-ray Absorptiometry Method — 44.5; 48.8; 43.8; 46.6 percent of total fat mass
Phase 2 N=42 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration. — -2.3 Change in % of cells positive for Ki-67